GLENZOCIMAB AND STROKE

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Retrieved on: 
Saturday, October 30, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Newton, Safety, CMS, Neurology, GPVI, Research, Hoffmann-La Roche, Innovation, VI, Medicine, Patient, Texas, Mediolanum, Stroke, Memorial Hermann–Texas Medical Center, Chief executive officer, Paris, Paris-Sud University, Nature, Texas Medical Center, International, Company, Mobile stroke unit, CEO, Growth, National Institute, Children's Memorial Hermann Hospital, Biotechnology, Pharmaceutical industry, glenzocimab (ACT017), the Therapeutic Candidate, glenzocimab and Stroke, Acticor Biotech, GLENZOCIMAB (ACT017), THE THERAPEUTIC CANDIDATE, GLENZOCIMAB AND STROKE, ACTICOR BIOTECH

Acticor Biotech, a clinical stage biotechnology company working on treatment for the acute phase of thrombotic diseases, has been awarded the prix Galien Medstartup Award in the category BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY for its collaboration with Pr James Grotta at the Memorial Hermann Hospital, TX.

Key Points: 
  • Acticor Biotech, a clinical stage biotechnology company working on treatment for the acute phase of thrombotic diseases, has been awarded the prix Galien Medstartup Award in the category BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY for its collaboration with Pr James Grotta at the Memorial Hermann Hospital, TX.
  • This collaboration aims to prepare an international clinical trial ACTISAVE to evaluate the efficacy of glenzocimab in patients suffering from acute ischemic stroke.
  • This eighth edition of the Galien Medstartup Awards was chaired by Bernard Poussot, Director of Roche Holding and former Chairman & CEO of Wyeth.
  • This year again, the event featured a remarkable world-renowned panel, rewarding the most innovative projects in the healthcare industry.

Acticor Biotech Announces the Completion of Enrollment in its GARDEN Clinical Trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Retrieved on: 
Thursday, July 22, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, TIMI, Medicine, Clinical trials, Medical research, Health sciences, COVID-19 vaccines, Health, COVID-19 vaccine, therapeutic candidate glenzocimab (ACT017), glenzocimab and Stroke, Acticor Biotech, THERAPEUTIC CANDIDATE GLENZOCIMAB (ACT017), GLENZOCIMAB AND STROKE, ACTICOR BIOTECH

We are proud to have completed patient recruitment for phase 2 of the GARDEN trial using glenzocimab in SARS-Cov-2-related ARDS.

Key Points: 
  • We are proud to have completed patient recruitment for phase 2 of the GARDEN trial using glenzocimab in SARS-Cov-2-related ARDS.
  • Two countries, France and Brazil, have actively participated in including a total of 62 evaluable patients for the GARDEN trial.
  • Acticor Biotech has recently announced the completion of patient enrolment in ACTIMIS (NCT03803007), a multinational, multicenter, randomized, double-blind, placebo-controlled, single-parallel, escalating dose phase 1b/2a safety and efficacy study of glenzocimab.
  • Acticor Biotech is a clinical stage biotechnology company, a spin-off of INSERM, dedicated to developing an innovative treatment for acute thrombotic diseases, including ischemic stroke.